Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469932 | 1.00 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA | |
| SCHEMBL14028966 | 0.85 | PTGDR2 (0.51) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA | |
| SCHEMBL12674477 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA | |
| SCHEMBL5274610 | 0.81 | ESR1 (0.51) | CYP1A2CYP2C19CYP2C9ALDH1A1ESR1 | |
| SCHEMBL22337091 | 0.80 | CYP1A2 (0.55) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA | |
| SCHEMBL531737 | 0.79 | L3MBTL1 (0.47) | CYP1A2CYP2C19CYP2C9L3MBTL1MAPT | |
| SCHEMBL30760989 | 0.79 | L3MBTL1 (0.47) | CYP1A2CYP2C19CYP2C9L3MBTL1MAPT | |
| SCHEMBL5303747 | 0.79 | ESR1 (0.37) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA | |
| SCHEMBL12128991 | 0.79 | MRGPRX4 (0.55) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA | |
| SCHEMBL1440131 | 0.79 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CYP1A2 1906/4885CYP2C19 3169/4885CYP2C9 2445/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CYP1A2 2010/4885CYP2C19 3437/4885CYP2C9 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.